NCT03232892View on ClinicalTrials.gov

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 13, 2018

Primary Completion Date

September 11, 2019

Study Completion Date

September 11, 2019

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Trametinib

Trametinib 2mg, once daily, PO, 28-day cycles

Trial Locations (1)

94115

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

American Cancer Society, Inc.

OTHER

lead

University of California, San Francisco

OTHER